Posted by Michael Wonder on 01 Jul 2021
FDA approves supplemental new drug application for Adhansia XR (methylphenidate hydrochloride) extended release capsules
1 June 2021 - Phase 3 adult laboratory classroom study confirmed that Adhansia XR provided rapid and sustained symptom relief for up to 16 hours in adults diagnosed with ADHD with a safety profile similar to current approved stimulants for the treatment of ADHD.
Adlon Therapeutics announced that the U.S. FDA approved a supplemental new drug application to update the prescribing information for Adhansia XR (methylphenidate hydrochloride) extended-release capsules.
